Though this advantage is subdued with time and no difference in Hb levels can be observed 1 month later, the therapy with WBE still provides other benefits on shortening the time of hospitalisation, reducing the cost of hospitalisation, and tapering required GC dosage, which reduces the risk of nosocomial infection and medical consumption. This evidence concerns the gene GSTM1 and nosocomial infection.